Uploaded August 2026 | Updated September 2026, 1 week ago
BPC 157 shows anti-inflammatory promise, but the autoimmune risk isn't fully studied yet.
This peptide has caught attention for inflammatory bowel conditions and immune support, and early phase trials look interesting. But here's what concerns me as a physician: BPC 157 has molecular components that can mimic your body's own proteins.
That cross-reactivity means your immune system might start attacking your own tissue, potentially triggering autoimmune conditions. We need larger population studies before I can recommend it confidently.
The peptide therapy conversation requires careful counseling because we're still learning about long-term safety, especially around immune function.
Send this to someone asking about peptides.
#shorts
BPC 157 shows anti-inflammatory promise, but the autoimmune risk isn't fully studied yet.
This peptide has caught attention for inflammatory bowel conditions and immune support, and early phase trials look interesting. But here's what concerns me as a physician: BPC 157 has molecular components that can mimic your body's own proteins.
That cross-reactivity means your immune system might start attacking your own tissue, potentially triggering autoimmune conditions. We need larger population studies before I can recommend it confidently.
The peptide therapy conversation requires careful counseling because we're still learning about long-term safety, especially around immune function.
Send this to someone asking about peptides.
#shorts
